THE MASS TORT EVIDENCE PORTFOLIO: A Clinical Framework for Claimant Screening Causation Bellwether Selection and Litigation Strategy

A mass tort portfolio is only as strong as the evidence inside its claimant files.

High claim volume can conceal unverified exposure, incomplete records, weak chronology, unsupported causation, inconsistent classifications, and claims that will not withstand expert or defense scrutiny. The challenge is not collecting more information. It is determining what the available evidence means.

The Mass Tort Evidence Portfolio gives litigation teams a clinical framework for making those decisions. Michelle Carroll draws on more than four decades of healthcare experience to show how fragmented medical records can be converted into defensible intelligence for claimant screening, causation analysis, bellwether selection, settlement readiness, and portfolio strategy.

This is not another book about producing longer chronologies or summarizing every entry in the record. It addresses the questions that affect case value and litigation direction:

• Is the alleged exposure verified in the relevant clinical window?
• What was the claimant’s condition before the alleged event?
• Does the imaging support the reported mechanism and timeline?
• What changed, when did it change, and what confirms that change?
• What alternative explanations remain plausible?
• What evidence is missing, and could it change the decision?

The book introduces a seven-pillar architecture for reviewing mass tort evidence: Record Integrity, Baseline Profiling, Imaging Analysis, Timeline Reconstruction, Standard of Care Review, Regulatory and Compliance Overlay, and Causation Mapping. Together, these pillars create a repeatable path from claimant intake to litigation-ready output.

Readers are shown how to build defensible intake screens, use tiered review without reducing clinical analysis to a checklist, develop meaningful claimant cohorts, detect outliers, select bellwether candidates, test cases from the defense perspective, and determine whether a portfolio is ready for negotiation, expert investment, or further investigation. Separate chapters address quality assurance, responsible technology, professional boundaries, governance, and the controls needed to keep classifications consistent across a portfolio.

Four detailed worked files take the reader through the process from beginning to end:

• a pharmaceutical exposure claim with weak verification
• a medical device claim with conflicting imaging
• a toxic exposure claim with competing causes
• a strong claim hidden inside a weak cohort

Each file identifies the attorney’s decision, tests source integrity, reconstructs the clinical record, ranks competing explanations, documents uncertainty, assigns a defensible classification, and shows how the findings should be handed back to counsel. The cases also demonstrate how learning from one claimant can improve decisions across the portfolio.

Written for attorneys, nurses, paralegals, medical-legal analysts, claimant review teams, and litigation support professionals, The Mass Tort Evidence Portfolio provides a disciplined alternative to volume-driven review. It does not ask the analyst to act as the attorney, treating clinician, radiologist, toxicologist, or retained expert. It shows the analyst how to recognize the limits of the record, identify the right escalation point, and frame better questions for the professionals who hold those roles.

The objective is straightforward: stop weak assumptions from becoming expensive litigation problems, find strong claims that administrative screening can miss, and give counsel a clearer view of what the portfolio can and cannot support.

Better portfolio decisions begin with better evidence decisions, one claimant file at a time.